Can Ivermectin Combat Epilepsy? New Hope in the Fight Against Onchocerciasis
"A recent study in Cameroon reveals the impact of over a decade of ivermectin treatments on epilepsy rates in areas plagued by onchocerciasis, offering new insights into preventative healthcare."
Epilepsy affects millions worldwide, with a disproportionate burden falling on low- and middle-income countries. In certain regions, the parasitic disease onchocerciasis, also known as river blindness, has been linked to an increased risk of epilepsy. This connection has prompted researchers to explore innovative strategies for prevention, one of which involves the drug ivermectin.
A new study conducted in the Mbam and Sanaga river valleys of Cameroon, areas where onchocerciasis is endemic, sheds light on the long-term impact of ivermectin treatments on epilepsy rates. The research, spanning over a decade, offers encouraging evidence that community-directed treatment with ivermectin (CDTI) can play a significant role in modifying the epidemiology of epilepsy in these vulnerable populations.
This article breaks down the study's methodology, key findings, and implications for public health, particularly in regions grappling with the dual challenges of parasitic diseases and neurological disorders. Understanding the potential of ivermectin in this context could pave the way for more effective prevention strategies and improve the lives of countless individuals.
Ivermectin Coverage and Epilepsy Trends
Studies from onchocerciasis-endemic areas report that increasing ivermectin coverage is associated with lower epilepsy incidence, while anecdotal evidence suggests fewer seizures in people with onchocerciasis-associated epilepsy. A 2024 study in Mvolo County, South Sudan, found fewer new epilepsy and probable nodding syndrome cases after annual community-directed ivermectin treatment was introduced. However, reported ivermectin use declined from 64% of participants in 2019 to 24% in 2021, and mathematical modelling assessed 19 years of annual mass drug administration from 1998 to 2017 rather than establishing a universal treatment effect.
Evidence Still Requires Controlled Trials
One proposed randomized clinical trial in the Democratic Republic of Congo would compare seizure freedom in patients receiving immediate ivermectin with seizure freedom after delayed treatment four months later. Reports describing ivermectin as a promising adjunct for refractory epilepsy also state that randomized studies are needed to clarify optimal dosing, safety monitoring, and mechanistic correlates. These limitations mean that real-world evidence and community treatment studies have not yet replaced controlled clinical evaluation.
From Japanese Soil to River-Blindness Treatment
Ivermectin's development as a human drug is closely linked to onchocerciasis, the chronic filarial disease also known as river blindness. The drug is a semisynthetic derivative of avermectins, a compound family originating from a soil microorganism, and one account traces it to a soil sample collected in Japan in the mid-1970s. Ivermectin was approved for human use in 1987 and became an established treatment for onchocerciasis, among other parasitic infections.
Ivermectin's Impact: A Detailed Look at the Cameroon Study
Researchers conducted door-to-door surveys in two villages, Bilomo and Kelleng, in Cameroon during August 2017 and January 2018. The goal was to assess the prevalence of epilepsy after more than 13 years of CDTI. Epilepsy diagnoses were made using a standardized questionnaire and confirmed by a neurologist. Children aged 7–10 years were also tested for Ov16 antibodies to gauge onchocerciasis transmission rates. Findings were then compared with data collected from previous surveys in these same villages.
- Epilepsy Prevalence: The crude prevalence of epilepsy was 4.6% in Bilomo and 7.8% in Kelleng.
- Nodding Seizures: 15.6% of epilepsy cases involved nodding seizures.
- Age Shift: The median age of people with epilepsy (PWE) increased, suggesting ivermectin might be preventing new cases in younger residents.
- Decreased Prevalence: Standardized epilepsy prevalence in Kelleng decreased from 13.5% in 2004 to 9.3% in 2018.
- Ongoing Transmission: Despite the progress, 47.6% of children tested positive for Ov16 antibodies, indicating ongoing onchocerciasis transmission.
Promising Signals, Divided Interpretation
A November 2024 article explores ivermectin as a potential way to reduce seizures associated with onchocerciasis, while a 2024 animal study examined anticonvulsant effects in the lithium-pilocarpine-induced status epilepticus model. The animal work investigated ivermectin as a positive allosteric modulator of the GABA A receptor. However, a separate 2023 review critically assessed the preclinical and clinical evidence and argued that ivermectin is not a suitable candidate drug for epilepsy, so current reviews do not reach a uniform conclusion.
Evidence Gaps and Uncertain Benefit
The case for ivermectin in epilepsy remains uncertain because promising observations do not by themselves establish consistent seizure control. Questions about dosing, safety monitoring, biological mechanisms, and the reliability of treatment effects remain important limitations. Any proposed use should therefore be understood as investigational or adjunctive rather than as a proven replacement for established epilepsy care.
A Potential Adjunct, Not an Established Alternative
Ivermectin is being considered in a specific context: epilepsy associated with onchocerciasis and the treatment of its underlying parasitic infection. The available evidence includes modelling, observational findings, clinical research proposals, and preclinical studies, rather than a settled comparison with standard antiseizure medicines. This makes ivermectin difficult to evaluate as a broadly applicable epilepsy treatment, especially while expert reviews disagree about its suitability.
A Call to Action: Strengthening Onchocerciasis Elimination Programs
The study reinforces the importance of ivermectin in reducing epilepsy prevalence in onchocerciasis-endemic areas. The observed age shift in PWE further suggests that ivermectin may prevent new cases, particularly among younger individuals.
A Signal Worth Testing Carefully
Evidence from onchocerciasis-endemic areas links increased ivermectin coverage with reduced epilepsy incidence, and a randomized clinical trial was conducted to assess whether ivermectin decreases seizure frequency. A 2024 review reports that about one third of Ugandan patients experienced reduced seizure frequency or intensity after one 150 micrograms per kilogram dose. Researchers have also used mediation analysis to examine both ivermectin's direct effect and its indirect effect through reduced microfilarial density, but these findings support further evaluation rather than definitive proof of efficacy.
What Further Research Must Clarify
Future work should determine whether ivermectin consistently reduces seizures in onchocerciasis-associated epilepsy and whether any benefit is linked to parasite control, a direct neurological effect, or both. Studies will also need to clarify appropriate dosing, safety, treatment timing, and which patients are most likely to respond. Larger, well-controlled trials would be needed before the approach could be considered a standard epilepsy therapy.
Coverage Determines Real-World Impact
The potential population benefit of ivermectin depends not only on biological effectiveness but also on whether eligible people receive treatment. Community-directed programs may produce uneven coverage, limiting the impact that treatment could have on epilepsy patterns in endemic areas. Sustained delivery, participation, monitoring, and access to broader epilepsy care are therefore likely to shape real-world outcomes.
Treatment Effects Are Uneven
Reports of reduced seizure frequency or intensity in some Ugandan patients suggest that ivermectin may offer meaningful benefit for part of the affected population. At the same time, not every treated person will necessarily respond, and access to community treatment can vary substantially. For people living with onchocerciasis-associated epilepsy, ivermectin's practical value will depend on reliable parasite-control programs alongside appropriate epilepsy management.
However, the persistent onchocerciasis transmission, as indicated by Ov16 seropositivity in children, underscores the need to enhance current control measures. Suboptimal ivermectin coverage may be contributing to the ongoing transmission, calling for innovative strategies to improve participation and effectiveness.
By addressing the challenges in onchocerciasis control and strengthening elimination programs, we can move closer to a future where the burden of onchocerciasis-associated epilepsy is significantly reduced, improving the quality of life for vulnerable populations in Cameroon and beyond.